Abstract 420TiP
Background
EGFR TKIs are established as an effective treatment for patients with EGFRm+ NSCLC harboring common mutations (Del19 or L858R). However, 7% to 23% of NSCLC tumors harbor uncommon EGFR mutations, where EGFR TKI efficacy is less established. Up to 75% of patients treated with afatinib develop T790M resistance. Second-line osimertinib is highly effective in these patients. In the GioTag study, sequential afatinib and osimertinib was associated with encouraging outcomes (median TTF and OS: 28.1 and 41.3 months, respectively) in 203 patients who developed T790M mutations after first-line therapy in a real-world setting.
Trial design
This real-world, non-interventional, global, multi-center study (UpSwinG; NCT04179890) will enroll ∼400 patients with EGFR TKI-naïve advanced (stage IIIB/IV) EGFRm+ NSCLC treated with EGFR TKIs across ∼65 study centers in ≤11 countries. Pre-existing data will be retrospectively collected from medical records (paper or electronic); selection bias will be minimized where possible, including by selecting only consecutive patients meeting each of the inclusion criteria and none of the exclusion criteria. The study comprises two cohorts (∼200 patients each). Cohort 1 will include patients with tumors harboring uncommon or compound EGFR mutations who received first- or second-line EGFR TKI treatment. Cohort 2 will include patients with common EGFR mutations who progressed on first-line afatinib, tested positive for T790M and were subsequently treated with second-line osimertinib (40 or 80 mg/day). Key exclusion criteria include prior participation in other EGFRm+ NSCLC studies and patients with active brain metastases. Across both cohorts, the primary objective will be time on treatment, defined from the start of EGFR TKI treatment until the end of EGFR TKI treatment or death by any cause in cohort 1, and from the start of first-line until the end of second-line treatment or death by any cause in cohort 2. Secondary objectives include overall response rate, overall survival, and time on second-line treatment (in cohort 1). Thus far, 256 patients have been recruited: 206 in cohort 1, and 50 in cohort 2.
Clinical trial identification
NCT04179890.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
S. Miura: Advisory/Consultancy, Speaker Bureau/Expert testimony: Chugai Pharma; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Speaker Bureau/Expert testimony: Taiho Pharma; Speaker Bureau/Expert testimony: Ono Pharma; Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Speaker Bureau/Expert testimony: Novartis; Speaker Bureau/Expert testimony: Abbvie; Speaker Bureau/Expert testimony: Kyowa Hakko Kirin. A. Märten: Full/Part-time employment: Boehringer Ingelheim. S. Popat: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Takeda; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AZ; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy: EMD Serono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Guardant Health; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Incyte; Honoraria (self), Advisory/Consultancy: Paradox; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Ariad.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session